• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical investigation >Abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer: review of clinical data
【24h】

Abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer: review of clinical data

机译：醋酸阿比特龙治疗转移性去势抵抗性前列腺癌：临床资料回顾

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abirateroneacetate(AA),aftermetabolizationtoabiraterone,isanoral inhibitor of the cytochrome P450C17 (CYP17) complex. It inhibits the production of androgens by interfering withhthe enzymes C17a hydroxylase and C17-C20 lyase. It was tested in patients with metastatic castration-resistant prostate cancer and showed promising results in Phase I and II studies with prostate specific antigen and radiological responses. In a randomized Phase III trial, AA in combination with prednisone increased median overall survival compared with prednisone alone in progressive docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Side effects of AA were mild with urinary tract infections, edema and hypokalemia when used in combination with prednisone. There was an influence on pharmacokinetic parameters in patients with renal and moderate hepatic failure without severe clinical complications and no dose adjustments are necessary. AA is a potent inhibitor of CYP2D6 and CYP1A2, and can interact with the metabolism of other drugs as shown in 'in vitro' studies.
机译：在代谢成阿比特龙后，阿比特龙乙酸酯（AA）是细胞色素P450C17（CYP17）复合物的鼻窦抑制剂。它通过干扰酶C17a羟化酶和C17-C20裂解酶来抑制雄激素的产生。它在具有转移性去势抵抗性前列腺癌的患者中进行了测试，并在具有前列腺特异性抗原和放射学反应的I和II期研究中显示出令人鼓舞的结果。在一项随机III期试验中，与进行泼尼松龙治疗的转移性去势抵抗性前列腺癌患者相比，AA与泼尼松联合治疗的总生存期较单独泼尼松增加。与强的松联合使用时，AA的副作用较轻，伴有尿路感染，水肿和低钾血症。没有严重临床并发症的肾和中度肝功能衰竭患者的药代动力学参数会受到影响，因此无需调整剂量。 AA是CYP2D6和CYP1A2的有效抑制剂，可与其他药物的代谢相互作用，如“体外”研究所示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号